

CR  SCITA
T H E R A P E U T I C S

First Quarter 2020 Interim Report

CRESCITA THERAPEUTICS INC.
CONSOLIDATED INTERIM STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)

		Three months ended March 31, 2020	Three months ended March 31, 2019
<i>(In thousands of Canadian dollars, except per share data and number of shares)</i>			
	Notes	\$	\$
Revenues	8	3,815	4,249
Operating expenses			
Cost of goods sold	4, 11	1,351	1,227
Research and development	9, 11	228	267
Selling, general and administrative	9, 11	2,183	1,932
Depreciation and amortization	11	414	356
Operating profit (loss)		(361)	467
Other expenses (income)			
Interest expense		92	159
Interest income		(89)	(35)
Foreign currency (gain) loss		(50)	65
Total other (income) expenses		(47)	189
Income (loss) before income taxes		(314)	278
Deferred income tax expense		180	236
Net income (loss)		(494)	42
Other comprehensive income (loss) to be reclassified to net income (loss) in subsequent periods			
Unrealized gain (loss) on translation of foreign operations (net of income taxes)		(8)	285
Total comprehensive income (loss)		(502)	327
Net loss per common share	10		
- basic		\$(0.02)	\$ -
- diluted		\$(0.02)	\$ -
Weighted average number of common shares outstanding	10		
- basic		20,700,133	21,016,059
- diluted		22,288,869	21,016,059

See accompanying Notes.

